Mostrar el registro sencillo del ítem

Rapid decrease in IL-1Ra and IP-10 plasma levels following tuberculosis treatment initiation

dc.rights.licenseopenen_US
dc.contributor.authorPEAN, Polidy
dc.contributor.authorAFFI, Roseline
hal.structure.identifierBordeaux population health [BPH]
hal.structure.identifierGlobal Health in the Global South [GHiGS]
dc.contributor.authorCHAZALON, Corine
dc.contributor.authorSOUMAHORO, Ben Cheick
hal.structure.identifierBordeaux population health [BPH]
hal.structure.identifierGlobal Health in the Global South [GHiGS]
dc.contributor.authorGABILLARD, Delphine
dc.contributor.authorDIM, Bunnet
dc.contributor.authorBORAND, Laurence
dc.contributor.authorMOH, Raoul
hal.structure.identifierBordeaux population health [BPH]
hal.structure.identifierGlobal Health in the Global South [GHiGS]
dc.contributor.authorANGLARET, Xavier
dc.contributor.authorBLANC, Francois-Xavier
dc.contributor.authorGIRARD, Pierre-Marie
dc.contributor.authorCARCELAIN, Guislaine
dc.contributor.authorLAUREILLARD, Didier
dc.contributor.authorWEISS, Laurence
dc.date.accessioned2024-06-26T14:27:27Z
dc.date.available2024-06-26T14:27:27Z
dc.date.issued2024-08-01
dc.identifier.issn1878-3511en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/200662
dc.description.abstractEnOBJECTIVES: Monitoring tools that could provide quick predictions of tuberculosis (TB) treatment outcomes are urgently needed. Here, we assessed whether the evolution of selected biomarkers of innate immunity may help monitoring TB treatment response within 2 weeks of treatment initiation. METHODS: ANRS12394-LILAC-TB was a proof-of-concept prospective study: adults with a rifampicin-susceptible TB who are HIV-negative and HIV-infected documented by a positive Xpert MTB/RIF test were enrolled in Cambodia and Côte d'Ivoire. Plasma concentrations of interleukin-1 receptor antagonist (IL-1Ra), interferon-γ-induced protein-10 and clusters of differentiation (CD) (scavenging CD163) were measured by commercial enzyme-linked immunosorbent assay kits. A Wilcoxon test for paired data was used for longitudinal comparisons. RESULTS: A total of 55 patients were enrolled (women: 31%, median age: 37 years; median CD4 count in the 10 of 13 participants with HIV: 53 cells/mm(3)). Overall, 83% were considered in TB treatment success. Compared with baseline, the IL-1Ra plasma levels significantly decreased as soon as week (W) 1, independent of HIV status (-71% in HIV-positive vs -33% in HIV-negative; P <0.001). The IP-10 plasma levels significantly decreased at W1 and W2 compared with baseline (P <0.0001); however, that decrease was less marked in participants with HIV. CONCLUSIONS: Our findings suggest that measuring IL-1Ra plasma levels with a standard enzyme-linked immunosorbent assay technique at baseline and then 1 week after TB treatment onset could help clinicians to quickly assess TB treatment response.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subject.enBiomarkers
dc.subject.enHIV
dc.subject.enTreatment response
dc.subject.enTuberculosis
dc.title.enRapid decrease in IL-1Ra and IP-10 plasma levels following tuberculosis treatment initiation
dc.title.alternativeInt J Infect Disen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1016/j.ijid.2024.107096en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed38740279en_US
bordeaux.journalInternational Journal of Infectious Diseasesen_US
bordeaux.page107096en_US
bordeaux.volume145en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamGHIGS_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.identifier.funderIDAgence Nationale de Recherches sur le Sida et les Hépatites Viralesen_US
bordeaux.identifier.funderIDInstitut de Recherche pour le Développementen_US
hal.identifierhal-04626309
hal.version1
hal.date.transferred2024-06-26T14:27:30Z
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft.jtitle=International%20Journal%20of%20Infectious%20Diseases&amp;rft.date=2024-08-01&amp;rft.volume=145&amp;rft.spage=107096&amp;rft.epage=107096&amp;rft.eissn=1878-3511&amp;rft.issn=1878-3511&amp;rft.au=PEAN,%20Polidy&amp;AFFI,%20Roseline&amp;CHAZALON,%20Corine&amp;SOUMAHORO,%20Ben%20Cheick&amp;GABILLARD,%20Delphine&amp;rft.genre=article


Archivos en el ítem

Thumbnail
Nombre:
BPH_Int JInfectDis_2024_Pean.pdf
Tamaño:
636.8Kb
Formato:
PDF
Ver/Abrir
Thumbnail
Nombre:
license_rdf
Tamaño:
914bytes
Formato:
application/rdf+xml
Ver/Abrir

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem